Clinical characteristics and prognostic factors of plasmablastic lymphoma patients
11 Jun 2016
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients
RNA regulation of JAK-STAT pathways in CML
Stopping tyrosine kinase inhibitors in CML
Evaluation of ibrutinib in treatment of CLL with 17p deletion
Sequencing analysis with circulating DNA
Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma
Daratumumab slows progression in refractory multiple myeloma
Recent developments in targeted therapies
MyPathway guidance of targeted therapy based on molecular profiles
Upfront autologous stem cell transplantation for newly diagnosed multiple myeloma
Advanced RET-rearranged NSCLC
Update on olaparib in ovarian cancer